The Effects of Gastric Acid Suppression on the Colonic Microbiome

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omeprazole (Primary)
Indications Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Zollinger-Ellison syndrome
Focus Pharmacodynamics

Most Recent Events

13 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
26 Mar 2014 Planned end date changed from 1 Jul 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
26 Mar 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight